

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT7025982

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST
<b>SEQUENCE:</b>	2

## CONVEYING PARTY DATA

Name	Execution Date
PAREXEL INTERNATIONAL CORPORATION	11/15/2021
PAREXEL INTERNATIONAL, LLC	11/15/2021

## RECEIVING PARTY DATA

<b>Name:</b>	OWL ROCK CAPITAL CORPORATION
<b>Street Address:</b>	399 PARK AVENUE
<b>City:</b>	NEW YORK
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10022

## PROPERTY NUMBERS Total: 8

Property Type	Number
Patent Number:	8620680
Patent Number:	10311534
Application Number:	16430263
Application Number:	15606676
Application Number:	17012319
Application Number:	17355046
Application Number:	16815873
Application Number:	15796583

## CORRESPONDENCE DATA

Fax Number:

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

Phone: 2023704750

Email: ipteam@cogencyglobal.com

Correspondent Name: JOANNA MCCALL

Address Line 1: 1025 CONNECTICUT AVE NW, SUITE 712

Address Line 2: COGENCY GLOBAL INC.

Address Line 4: WASHINGTON, D.C. 20036

<b>ATTORNEY DOCKET NUMBER:</b>	1523842 2L
--------------------------------	------------

PATENT

<b>NAME OF SUBMITTER:</b>	ANNA MARCUS
<b>SIGNATURE:</b>	/Anna Marcus/
<b>DATE SIGNED:</b>	11/16/2021
<b>Total Attachments: 6</b> source=B To File - Phoenix - 2L Patent Security Agreement [Executed]#page3.tif source=B To File - Phoenix - 2L Patent Security Agreement [Executed]#page4.tif source=B To File - Phoenix - 2L Patent Security Agreement [Executed]#page5.tif source=B To File - Phoenix - 2L Patent Security Agreement [Executed]#page6.tif source=B To File - Phoenix - 2L Patent Security Agreement [Executed]#page7.tif source=B To File - Phoenix - 2L Patent Security Agreement [Executed]#page8.tif	

## SECOND LIEN PATENT SECURITY AGREEMENT

SECOND LIEN PATENT SECURITY AGREEMENT dated as of November 15, 2021 (this "Agreement"), among Parexel International Corporation and Parexel International, LLC (each a "Grantor") and Owl Rock Capital Corporation ("Owl Rock") in its capacity as collateral agent for the Secured Parties party to the Credit Agreement referred to below (in such capacity, the "Collateral Agent").

WHEREAS, reference is made to (a) the Second Lien Credit Agreement dated as of November 15, 2021, (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the "Credit Agreement"), by and among Phoenix Midco, Inc., a Delaware corporation ("Holdings"), Phoenix Newco, Inc., a Delaware corporation (the "Borrower"), the Subsidiary Borrowers from time to time party thereto, the lenders from time to time party thereto and Owl Rock, as administrative agent and collateral agent and (b) the Second Lien Pledge and Security Agreement dated as of November 15, 2021 (the "Security Agreement"), by and among Holdings, the Borrower, the Subsidiary Parties from time to time party thereto, the Additional Parties from time to time party thereto and the Collateral Agent;

WHEREAS, the Lenders have agreed to extend credit to the Borrower subject to the terms and conditions set forth in the Credit Agreement; and

WHEREAS, each Grantor is willing to execute and deliver this Agreement as consideration for such extensions of credit.

NOW, THEREFORE, for good and valuable consideration, the sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

SECTION 1. Terms. Capitalized terms used in this Agreement and not otherwise defined herein have the meanings specified in the Security Agreement or the Credit Agreement, as applicable.

SECTION 2. Grant of Security Interest. As security for the payment or performance, as the case may be, in full of the Secured Obligations, each Grantor hereby grants to the Collateral Agent, its successors and assigns, for the benefit of the Secured Parties, a security interest (the "Security Interest") in all of such Grantor's right, title and interest in, to and under any Patents now owned or at any time hereafter acquired by such Grantor, including those listed on Schedule I (the "Collateral").

SECTION 3. Security Agreement. The Security Interest granted to the Collateral Agent herein is granted in furtherance, and not in limitation, of the security interests granted to the Collateral Agent pursuant to the Security Agreement. Each Grantor hereby acknowledges and affirms that the rights and remedies of the Collateral Agent with respect to the Collateral are more fully set forth in the Security Agreement, the terms and provisions of which are hereby incorporated herein by reference as if fully set forth herein. In the event of any conflict between the terms of this Agreement and the Security Agreement, the terms of the Security Agreement shall govern.

SECTION 4. Counterparts. This Agreement may be executed in counterparts (and by different parties hereto on different counterparts), each of which shall constitute an original but all of which when taken together shall constitute a single contract. Any signature to this Agreement may be delivered by facsimile, electronic mail (including pdf)

or any electronic signature complying with the U.S. federal ESIGN Act of 2000 or the New York Electronic Signature and Records Act or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes to the fullest extent permitted by applicable law.


SECTION 5. CHOICE OF LAW. THIS AGREEMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS AGREEMENT, WHETHER IN TORT, CONTRACT (AT LAW OR IN EQUITY) OR OTHERWISE, SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.

SECTION 6. *INTERCREDITOR AGREEMENT GOVERNS*. NOTWITHSTANDING ANYTHING HEREIN TO THE CONTRARY, THE LIENS AND SECURITY INTERESTS GRANTED TO THE COLLATERAL AGENT FOR THE BENEFIT OF THE SECURED PARTIES PURSUANT TO THIS AGREEMENT AND THE EXERCISE OF ANY RIGHT OR REMEDY BY THE COLLATERAL AGENT WITH RESPECT TO ANY COLLATERAL HEREUNDER ARE SUBJECT TO THE PROVISIONS OF THE CLOSING DATE INTERCREDITOR AGREEMENT, ANY EQUAL PRIORITY INTERCREDITOR AGREEMENT AND ANY OTHER ACCEPTABLE INTERCREDITOR AGREEMENT. IN THE EVENT OF ANY CONFLICT BETWEEN THE PROVISIONS OF THE CLOSING DATE INTERCREDITOR AGREEMENT, ANY ACCEPTABLE INTERCREDITOR AGREEMENT (INCLUDING THE EQUAL PRIORITY INTERCREDITOR AGREEMENT) AND THIS AGREEMENT, THE PROVISIONS OF THE CLOSING DATE INTERCREDITOR AGREEMENT, ANY EQUAL PRIORITY INTERCREDITOR AGREEMENT AND ANY SUCH ACCEPTABLE INTERCREDITOR AGREEMENT SHALL GOVERN AND CONTROL.

[Signature Pages Follow]


IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the day and year first above written.

OWL ROCK CAPITAL CORPORATION, as  
Administrative Agent

By:   
Name: Jeff Walwyn  
Title: Authorized Signatory

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the day and year first above written.

PAREXEL INTERNATIONAL CORPORATION

By:    
56BE7679992C42D...  
Name: John Benoit  
Title: Treasurer

PAREXEL INTERNATIONAL, LLC

By:    
56BE7679992C42D...  
Name: John Benoit  
Title: Treasurer

**SCHEDULE I****U.S. PATENTS**

<b>PATENT</b>	<b>JURISDICTION</b>	<b>PATENT NUMBER</b>	<b>REGISTERED OWNER</b>	<b>ISSUE DATE</b>
<b>METHODS AND APPARATUS FOR PLANNING AND MANAGEMENT OF CLINICAL TRIALS</b>	United States of America	8,620,680	PAREXEL International Corporation	December 31, 2013
<b>METHODS AND APPARATUS FOR PLANNING AND MANAGEMENT OF CLINICAL TRIALS</b>	United States of America	10,311,534	PAREXEL International Corporation	June 4, 2019

**U.S. PATENT APPLICATIONS**

<b>PATENT</b>	<b>JURISDICTION</b>	<b>APPLICATION NUMBER</b>	<b>APPLICANT</b>	<b>FILING DATE</b>
<b>METHODS AND APPARATUS FOR PLANNING AND MANAGEMENT OF CLINICAL TRIALS</b>	United States of America	16/430,263	PAREXEL International Corporation	June 3, 2019
<b>DECISION SUPPORT SYSTEM FOR CNS DRUG DEVELOPMENT</b>	United States of America	15/606,676	PAREXEL International Corporation	May 26, 2017
<b>SEMANTIC PARSING ENGINE</b>	United States of America	17/012,319	PAREXEL International, LLC	September 4, 2020
<b>DATA STORAGE AND RETRIEVAL SYSTEM INCLUDING A KNOWLEDGE GRAPH EMPLOYING MULTIPLE SUBGRAPHS AND A LINKING LAYER INCLUDING MULTIPLE LINKING NODES, AND METHODS, APPARATUS AND SYSTEMS FOR CONSTRUCTING AND USING SAME</b>	United States of America	17/355,046	PAREXEL International, LLC	June 22, 2021
<b>METHODS, APPARATUS AND SYSTEMS FOR ANNOTATION OF TEXT DOCUMENTS</b>	United States of America	16/815,873	PAREXEL International, LLC	March 11, 2020

<b>DATASET NETWORKING AND DATABASE MODELING</b>	United States of America	15/796,583	PAREXEL International, LLC	October 27, 2017
---	-----------------------------	------------	----------------------------------	------------------